As winter settles over Australia, it's not just the drop in temperature we notice—there's also a sharp rise in respiratory illnesses. Most of us are familiar with the usual winter players such as ...

MPV tends to hit hardest in young children, older adults and people with weakened immune systems. A virologist explains.

Respiratory syncytial virus (RSV) is the most common single cause of respiratory hospitalisation of infants and is the second largest cause of lower respiratory infection mortality worldwide. In ...

COVID-19 has now surpassed rhinovirus to become the most prevalent respiratory virus in circulation. "The COVID-19 positivity rate is trending upward this month, with higher rates in southern ...

The agency noted it is not an indication that respiratory virus activity has peaked and that such activity "is expected to continue for several more weeks." STOCK PHOTO/Getty Images.

While monoclonal antibodies have been approved to treat respiratory syncytial virus (RSV) in infants and young children in Germany, the German regulatory body for vaccinations—the German ...

The RSV vaccine can protect against respiratory syncytial virus infections, especially in infants and people at high risk.

Objective The 2022 Australian winter was the first time that COVID-19, influenza and respiratory syncytial virus (RSV) were circulating in the population together, after two winters of physical ...

Promising early data from Luxembourg after the start of immunising children with a monoclonal antibody in 2023: overall hospitalisations due to infection with respiratory syncytial virus (RSV ...

Human respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infection (ALRI) in infants and young children. 1,2 We previously estimated that, globally in 2019, there were ...